Dr. Lindsay Rosenwald: Developing Effective, Life-Saving Drugs

Although he opted to give up his private practice as a physician to focus on venture capital financing, investment banking and asset management, Dr. Lindsay Rosenwald was never disconnected from the medical industry. He merely chose a much bigger venue that provided him with a larger scope of influence to help the healthcare industry in a deeper, broader level. A pioneering and consistent leader in the biotechnology and life sciences research investment, he has founded, financed and recapitalized countless public and private biotechnology and life-sciences companies and has been instrumental in the research, development and creation of several important drugs in the market today.
Undeniably, one of the most prominent figures in the finance and the biotechnology world, Dr. Lindsay Rosenwald has been at the reins of life-sciences and biotech advancement. His passion is to assist emerging and start-up companies with their funding and research resources. He is aware that adequate financial support plays a most significant role in the research and development of life-saving drugs. For almost twenty years, he has invested time, money and expertise to continuously improve the way diseases are diagnosed and treated and the way patients are cared for. His mission is to bring quality healthcare and provide effective medication to people who are troubled with difficult illnesses. And his vision is a world with sophisticated healthcare and medical services, with people enjoying better, healthier lives.
Through the years, Dr. Lindsay Rosenwald’s portfolio of companies has achieved remarkable successes. Polarx BioPharmaceuticals, Inc. set a groundbreaking record in the biotech industry when it received Food and Drug Administration approval for its cancer drug, Arsenic Trioxide, after being researched and tested for only 30 months. Dr. Rosenwald was also behind’s Cougar Biotechnology’s triumph. This biotech company has developed abiraterone acetate, a drug for patients with advanced stage of prostate cancer. Though rare for any drug to be considered before Phase III trials, abiraterone acetate has demonstrated so much potential that made in Johnson & Johnson to purchase the firm in 2009 in a “short-term merger” for approximately $1 billion. And according to Cougar, abiraterone acetate continues to show convincing proof of anticancer activity in patients with advanced castrate-resistant prostate cancer.